AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 04. Aprel ,2026

RENAL ELIMINATION OF MEDICINES: RENAL CLEARANCE, DOSE INDIVIDUALIZATION, AND THE EFFECT OF NEPHROTOXIC DRUGS

Qurbanova Gulnoza Abdurayim qizi
Termez University of Economics and Service
Teacher of the Department of Morphological Sciences, Faculty of Medicine
e-mail: gulnozaqurbonova528@gmail.com
ORCID: 0009-0002-4853-8937
Eshqobilov Ozodbek Abdusodiqovich
Termez University of Economics and Service
Assistant of the Department of Fundamental Sciences, Faculty of Medicine
Email: ozotbekbestboy@gmail.com

Abstract

This article examines renal drug elimination as a critical determinant of pharmacokinetic safety. It reviews glomerular filtration, tubular secretion, tubular reabsorption, renal clearance, estimation of kidney function and nephrotoxicity risk. Results show that renal impairment changes both drug exposure and adverse effect risk. The article argues that dose individualization must be understood as a safety framework rather than a mechanical arithmetic procedure.

Keywords

renal clearance, drug elimination, kidney function, nephrotoxicity, pharmacokinetics, CKD

Introduction

The kidney is not merely an excretory filter; it is an active pharmacokinetic organ. Many medicines and metabolites leave the body through glomerular filtration, tubular secretion and tubular reabsorption. When kidney function declines, the same exposure that was safe before may become excessive, especially for medicines with renal elimination, narrow therapeutic index or active metabolites.

Renal clearance links physiology with clinical pharmacology. It expresses the apparent volume of plasma cleared of a substance per unit time, but its practical meaning is broader: it tells the clinician how strongly a medicine depends on kidney function. The risk is highest when impaired elimination combines with dehydration, sepsis, heart failure, older age, diabetes, concurrent nephrotoxins or contrast exposure.

A weak article on this topic would simply list nephrotoxic medicines. A stronger article must explain mechanisms, risk stratification and the logic of dose individualization without converting the discussion into unsafe self-dosing instructions.

Literature Review

KDIGO 2024 guidance emphasizes validated estimation of glomerular filtration rate and risk-based management of chronic kidney disease. Global data show that chronic kidney disease affects hundreds of millions of adults, making renal pharmacology a population-level issue rather than a rare specialist concern.

Uzbek pharmacology and clinical pharmacology sources describe excretion, drug accumulation and toxic reactions as important elements of rational pharmacotherapy. These

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 04. Aprel ,2026

sources are especially useful for teaching because they connect physiology with bedside reasoning. International literature adds updated epidemiology and standardized kidney-function terminology.

Nephrotoxicity mechanisms include direct tubular toxicity, hemodynamic changes, crystal nephropathy, interstitial inflammation and rhabdomyolysis-associated injury. The key practical point is that toxicity is usually multifactorial; kidney injury is rarely explained by a single molecule alone.

Materials and Methods

To keep the article clinically safe, exact dose instructions are not provided. Instead, the analysis focuses on principles: when renal elimination matters, which patient variables increase risk, and why laboratory and clinical monitoring should guide professional decisions.

Results

Table 1. Renal elimination mechanisms and pharmacological meaning

Mechanism	Description	Clinical risk
Glomerular filtration	Passive filtration of unbound drug	Reduced GFR increases exposure of renally cleared medicines
Tubular secretion	Active transporter-mediated movement into tubule	Transporter competition may cause interactions
Tubular reabsorption	Return of drug from tubule to blood	pH, lipophilicity and urine flow can change elimination
Metabolite elimination	Renal removal of active or toxic metabolites	Metabolite accumulation may cause delayed toxicity

Table 2. Conceptual renal-risk groups of medicines

Group	Why kidney function matters	Risk-management logic
Predominantly renal elimination	Parent drug clearance depends on GFR/secretion	Professional dose individualization and monitoring
Active metabolites	Metabolites may accumulate despite normal parent-drug kinetics	Watch for delayed adverse effects
Narrow therapeutic index	Small exposure increase may become clinically important	Laboratory and symptom monitoring
Potentially nephrotoxic agents	May worsen kidney function and reduce their own elimination	Avoid unnecessary combinations and dehydration

Table 3. Global kidney-disease context used in risk interpretation

Indicator	Reported value	Interpretation
Global adult CKD burden, 2023	About 788 million adults aged 20+ estimated to	Renal pharmacology is relevant at population scale

AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 04. Aprel ,2026

	have CKD	
Global age-standardized CKD prevalence, adults	About 14.2%	Kidney-function assessment should not be an afterthought
Kidney failure requiring replacement therapy, 2023	About 4.59 million cases globally	Advanced disease increases medication-safety complexity



The results show a simple but often ignored chain: lower kidney function leads to slower elimination; slower elimination increases exposure; increased exposure raises adverse-effect risk; adverse effects may further impair kidney function. This vicious cycle is most likely in frail patients and during acute illness.

Renal clearance is also an interaction site. Transporter competition can change elimination even when GFR appears stable. Therefore, kidney safety cannot be reduced to a single creatinine value; it requires trend interpretation, clinical context and review of concomitant medicines.

Discussion

The major tradeoff in renal pharmacology is between undertreatment and toxicity. Excessive fear of renal impairment can deny effective therapy; ignoring impairment can produce accumulation. The correct solution is not routine avoidance but structured individualization by professionals.

The most common failure mode is using serum creatinine alone without considering age, body composition and acute changes. Another failure mode is assuming that a stable chronic kidney disease patient and an acutely dehydrated patient have the same drug-handling capacity. The latter may be far more vulnerable.

For medical education, renal elimination should be taught alongside clinical scenarios: older patient, diabetes, heart failure, infection, polypharmacy and low fluid intake. This creates stronger reasoning than memorizing lists of nephrotoxic medicines.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 04. Aprel ,2026

Conclusion

Renal elimination determines the safety of many medicines through filtration, secretion, reabsorption and metabolite clearance. Renal impairment changes exposure and can magnify toxicity, especially in patients with CKD, acute illness, dehydration or polypharmacy. The practical conclusion is strict: kidney function must be treated as a dynamic safety variable. Dose individualization is a professional clinical process, not a patient-led adjustment.

References / Foydalanilgan adabiyotlar

1. Azizova S.S. Farmakologiya. Toshkent: Abu Ali ibn Sino nomidagi tibbiyot nashriyoti, 1994.
2. Mavlyanov I.R., Mahkamova R.K., Kats P. Klinik farmakologiya. Toshkent: tibbiyot oliy ta'lim muassasalari uchun darslik.
3. Mamadov Yu.M. Klinik farmakologiya. Toshkent, 2010.
4. Gadayev A.G. Ichki kasalliklar propedevtikasi. Toshkent, 2018.
5. KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 2024.
6. Awdishu L. et al. KDIGO 2024 clinical practice guideline update. Kidney International Reports/PMC, 2025.
7. Mark P.B. et al. Global, regional, and national burden of chronic kidney disease in 2023. The Lancet, 2025.
8. Susa S.T. et al. Drug Metabolism. StatPearls/NCBI Bookshelf, 2023.
9. Mirkov S. et al. Estimation of kidney function for medication dosing in adult patients. Journal of Pharmacy Practice and Research, 2024.
10. International Society of Nephrology. Global Kidney Health Atlas, 2023.